Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24

Rhea-AI Summary

Pfizer (NYSE: PFE) has announced its virtual 2025 Annual Meeting of Shareholders, scheduled for April 24, 2025, at 9:00 a.m. EDT. Shareholders can access the meeting through https://meetnow.global/PFE2025, with login available from 8:45 a.m. EDT.

Participants will need a control number from their proxy card, voting instruction form, or notice to ask questions and vote during the meeting. Questions can be submitted in advance until 5:00 p.m. EDT on April 22. While most shareholders can vote during the meeting, some beneficial owners may need to obtain a legal proxy and pre-register.

The meeting will also be available in listen-only mode without a control number, and a replay will be accessible for up to one year at https://investors.pfizer.com/Investors/Events--Presentations. The virtual format ensures shareholders have comparable rights and opportunities as an in-person meeting.

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.

Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2025. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live meeting.

Shareholders also may submit questions in advance of the meeting by following the instructions provided on the “Rules of Conduct and Meeting Procedures” available on the virtual meeting platform. The deadline for submitting questions in advance of the meeting is 5:00 p.m. EDT on April 22. Both registered and most beneficial shareholders will be able to vote their shares during the meeting by following the instructions provided on the virtual meeting platform. Some beneficial owners may be required to obtain a legal proxy and pre-register for the virtual meeting in order to vote or ask questions during the live meeting. Beneficial owners should check with their broker as to whether pre-registration is required. In addition, beneficial owners will be required to obtain a legal proxy and pre-register in order to submit questions in advance of the live meeting.

No control number is required to participate in a listen-only mode. A replay of the webcast will be available for up to one year at: https://investors.pfizer.com/Investors/Events--Presentations.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The webcast of the meeting may include forward-looking statements about, among other things, our anticipated operating and financial performance, including financial guidance and projections; reorganizations, business plans, strategy, goals and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, size and utilization rates, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities; manufacturing and product supply; our ongoing efforts to respond to COVID-19, including our COVID-19 products; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250410600365/en/

Media Contact: PfizerMediaRelations@pfizer.com

+1 (212) 733-1226



Investor Contact: IR@Pfizer.com

+1 (212) 733-4848

Source: Pfizer Inc.

FAQ

When is Pfizer's 2025 Annual Shareholder Meeting and how can shareholders attend?

Pfizer's 2025 Annual Shareholder Meeting will be held virtually on April 24, 2025, at 9:00 a.m. EDT. Shareholders can attend by accessing https://meetnow.global/PFE2025 with their control number.

What do PFE shareholders need to participate and vote in the 2025 virtual meeting?

Shareholders need a control number from their proxy card, voting instruction form, or notice to participate fully and vote. Some beneficial owners may need to obtain a legal proxy and pre-register.

What is the deadline for PFE shareholders to submit questions before the 2025 annual meeting?

Shareholders must submit their questions by 5:00 p.m. EDT on April 22, 2025, following the instructions in the Rules of Conduct and Meeting Procedures.

How long will the replay of PFE's 2025 annual meeting be available?

The meeting replay will be available for up to one year at https://investors.pfizer.com/Investors/Events--Presentations.

What time can PFE shareholders begin logging into the 2025 virtual annual meeting?

Shareholders can begin logging into the virtual meeting platform at 8:45 a.m. EDT on April 24, 2025, 15 minutes before the meeting starts.